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Abstract
Background: The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by 
conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and 
enhance the effect of non-targeted PDT (ntPDT) for cancer. fVII is a natural ligand for receptor tissue factor (TF) with 
high affinity and specificity. The reason for targeting receptor TF for the development of tPDT is that TF is a common 
but specific target on angiogenic tumour vascular endothelial cells (VEC) and many types of tumour cells, including 
solid tumours and leukaemia.
Methods: Murine factor VII protein (mfVII) containing a mutation (Lys341Ala) was covalently conjugated via a cross 
linker EDC with Veterporfin (VP) that was extracted from liposomal Visudyne, and then free VP was separated by 
Sephadex G50 spin columns. fVII-tPDT using mfVII-VP conjugate, compared to ntPDT, was tested in vitro for the killing of 
breast cancer cells and VEGF-stimulated VEC and in vivo for inhibiting the tumour growth of breast tumours in a mouse 
xenograft model.
Results: We showed that: (i) fVII protein could be conjugated with VP without affecting its binding activity; (ii) fVII-tPDT 
could selectively kill TF-expressing breast cancer cells and VEGF-stimulated angiogenic HUVECs but had no side effects 
on non-TF expressing unstimulated HUVEC, CHO-K1 and 293 cells; (iii) fVII targeting enhanced the effect of VP PDT by 
three to four fold; (iii) fVII-tPDT induced significantly stronger levels of apoptosis and necrosis than ntPDT; and (iv) fVII-
tPDT had a significantly stronger effect on inhibiting breast tumour growth in mice than ntPDT.
Conclusions: We conclude that the fVII-targeted VP PDT that we report here is a novel and effective therapeutic with 
improved selectivity for the treatment of breast cancer. Since TF is expressed on many types of cancer cells including 
leukaemic cells and selectively on angiogenic tumour VECs, fVII-tPDT could have broad therapeutic applications for 
other solid cancers and leukaemia.
Background
Accumulating evidence suggests that the receptor tissue
factor (TF) is expressed on endothelial cells of pathologi-
cal blood vessels associated with solid tumours [1-6], wet
macular degeneration (wMD) [7,8], and endometriosis[9]
but not on endothelial cells of normal blood vessels [1-
5,10-13], providing an accessible and specific therapeutic
target for these diseases. Because its natural ligand, factor
VII (fVII), binds TF with exceptionally high specificity
and affinity (up to 10-12 M) [14], we constructed an anti-
body-like immunoconjugate (Icon) by fusing two fVII
peptides to an IgG1 Fc to target TF for the development
of a novel immunotherapy [2-4]. Since the binding of fVII
to TF would initiate an extrinsic coagulation cascade [15],
we introduced a single mutation (K341A) to fVII peptide
to reduce its coagulation activity while retaining its bind-
ing activity to TF [2,4]. The choice of mutation was based
on a previous report [16], in which Dickinson et al.
showed that the TF binding activity of K341A mutated
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Page 2 of 13fVII was indistinguishable from wild-type fVII, whereas
its coagulation function was reduced about eight fold
[16]. Delivery of the Icon cDNA by an adenoviral vector,
or injection of the Icon protein, resulted in a cytolytic
immune attack against the pathological vessels in mouse
models of cancer [2-5], wMD [7,8], and endometriosis
[9].
Here, we test the use of monomeric fVII peptide to tar-
get a laser-activatable photosensitiser to TF for the devel-
opment of ligand-targeted photodynamic therapy (tPDT)
of cells expressing TF, particularly for the angiogenic vas-
cular endothelial cells (VECs) in solid tumours and the
choroidal neovasculature of wMD. In the case of cancer,
many types of cancer cells (including breast cancer cells)
also over-express TF, providing additional target cells for
fVII-targeted therapies. A widely used procedure for
non-targeted PDT (ntPDT) of wMD involves intravenous
injection of the photosensitiser Visudyne followed by
irradiation of the eye with a laser emitting 689 nm light,
in which Visudyne is activated by the laser light to gener-
ate singlet oxygen, resulting in cytoxicity and apoptosis of
cells [17]. However, because the non-targeted photosen-
sitiser could be absorbed by normal cells as well as by
pathological cells, side effects may be associated with this
procedure [18,19]. To improve the safety and efficacy of
PDT, tPDT has been proposed and tested by conjugating
the photosensitisers to antibodies or ligands for targeting
to cells expressing the cognate antigen or receptor [20-
23]. In this paper, we target the receptor TF by covalently
conjugating its ligand, fVII protein, to VP for the develop-
ment of a novel and effective fVII-tPDT for the treatment
of breast cancer in vitro and in vivo. Recently, we showed
that this fVII-tPDT using the fVII-VP conjugate was also
efficacious and safe for the treatment of wMD in a rat
model [24].
In the course of the development of TF-targeted thera-
peutics, Hu and Garen have previously developed
fVII(K341A)/IgG1 Fc (Icon) immunoconjugates for
immunotherapy of cancer [2-5], wMD [7,8], and endo-
metriosis[9]. Recently, Shoji and co-workers used an
active site-inactivated recombinant human fVII (fVIIa) to
target EF24, a synthetic curcumin analog, for TF-targeted
cancer therapy [25]. To the best of our knowledge, this
paper describes, for the first time, the use of fVII to target
its cognate receptor TF for the development of ligand-
tPDT, which has broad potential for the treatment of can-
cer and wMD [24].
Methods
Cell lines
Chinese Hamster Ovary K1 (CHO-K1, ATCC) cells were
grown in F12 medium, murine breast cancer EMT6 and
human embryonic kidney 293 cells (kindly provided by
Dr. Albert Deisseroth during his tenure at Yale Univer-
sity) in DMEM and human breast cancer MDA-MB-231
cells in RPMI1640 medium supplemented with 10% heat
inactivated fetal bovine serum (FBS) (Invitrogen) and
1:100 antibiotics (Sigma). Human umbilical vein endothe-
lial cells (HUVEC) purchased from Yale Vascular Biology
and Transplantation Group were grown in M199 (Invit-
rogen) with 20% heat inactivated FBS, 1:100 antibiotics,
and 1:100 Endothelial Cell Growth Supplement solution
(ECGS, BD Biosciences).
Construction of plasmid containing the mfVII cDNAs
The plasmid vector encoding mouse fVII peptide was
constructed by PCR amplifying the mouse fVII cDNA
with a K341A mutation from a previously constructed
Icon (GenBank accession number AF272773)
pcDNA3.1(+) plasmid vector as a DNA template [2] and
by using high-fidelity Pfx DNA polymerase (Invitrogen)





TC CCAGTAGTGGGAGT-3'. The amplified mfVII
(mfVII-Sp-His) cDNA contains the coding sequence for
mfVII (K341A), a BamHI site, ribonuclease S-peptide [Sp
(D14N), the first 15 amino acids at the N-terminus of
bovine ribonuclease S [26]] and eight histidines (His tag),
with a Hind III site at the 5'-end and a Not I site at the 3'-
end. The S peptide (Sp or S tag) and polyhistidines (His
tag) were designed to be included at the C-terminus of
the fVII protein for protein purification and detection.
The reason for using the Sp mutant (D14N) instead of
wild-type Sp in the fVII protein is that Kim JS and Raines
RT showed that Sp (D14N) had a higher affinity for S pro-
tein than wild-type Sp [26]. The PCR-amplified cDNAs
were sequentially digested with Hind III and Not I and
ligated into the pcDNA3.1(+) vector (Invitrogen).
Production and purification of the mfVII protein
The mfVII plasmid was transfected into CHO-K1 cells
using the Superfect transfection reagent (Qiagen), and
the transfectant clones were selected with 1 mg/ml G418
(Invitrogen). Individual clones were isolated using Clon-
ing Discs (Sigma) and grown in CHO serum-free
medium (SFM) Excel 301 (JRH Biosciences) supple-
mented with a final concentration of 1 μg/ml Vitamin K1
(Sigma) (for posttranslational modifications, particularly
vitamin K-dependent γ-carboxylation of fVII protein) [2-
4,27], and the SFM was collected every three to four days.
The clone with the highest expression of mfVII protein
was selected by Western blotting using anti-His tag anti-
body (Sigma) and expanded to 10 T175 flasks in F12-
complete growth medium with a final concentration of
0.5 mg/ml G418 (Gibco). When the cells reached about
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PBS and switched to SFM with Vitamin K1 as described
above. The SFM was collected twice a week. After centrif-
ugation to remove the suspended cells, the SFM was
pooled and stored at -20°C until affinity purification.
The mfVII was affinity purified using Ni-NTA resin
(Qiagen). The purified protein was dialysed against PBS
pH7.4 and concentrated to 1 mg/ml using a Millipore
Centrifugal device (MWCO 10,000). The affinity-purified
mfVII protein was characterised by SDS-PAGE for purity
and molecular weight. The mfVII protein was conjugated
with photosensitiser as described below or aliquoted and
stored at -20°C for future conjugation.
Extraction and conjugation of Verteporfin to mfVII protein
Chemically pure form of Verteporfin (Benzoporphyrin
derivative-monoacid ring A, BPD-MA, molecular weight
718.8) was not available at the time of the study so it was
extracted from clinic-leftover liposomal Visudyne (QLT
Inc) using an outlined procedure [28] with modifications
as follows. Five μl of 6 M HCl was added and mixed by
vortexing to 300 μl of Visudyne aqueous solution of clini-
cally reconstituted liposomal formulation, in which the
VP concentration was 2 mg/ml. Then, 500 μl of dichlo-
romethane (CH2Cl2) (Sigma) was added and mixed by
vortexing, followed by centrifugation for 5 min. After
centrifugation, the organic (VP, lower phase) and aqueous
(liposome, upper phase) layers were visibly separated.
The VP in the lower phase was carefully transferred to a
glass tube and loaded to a freshly prepared silica gel col-
umn (Sigma) equilibrated in CH2Cl2/methanol (3:1). The
VP was eluted using CH2Cl2/methanol (3:1), and the
green fractions containing VP were collected, pooled in a
glass beaker, aliquoted in 1.5-ml Eppendorf tubes and
dried in a SpeedVac. The weight of the VP powder was
determined by subtracting the weight of the Eppendorf
tube after dissolving and removing VP in dimethylforma-
mide (DMF, Sigma). The VP was adjusted to a final con-
centration of 10 mg/ml in DMF. A standard curve of VP
dye was generated by serially diluting a known concentra-
tion of VP in DMF into de-ionised and distilled H2O
starting from 1000 μg/ml. The equation was y = 0.00005 x
- 0.0008 (R2 = 0.9995), where y is the OD689 nm at a 1:50
dilution and x is the concentration of VP (μg/ml).
VP was conjugated to mfVII protein by EDC (N'-3-dim-
ethylaminopropyl-N-ethylcarbodiimide hydrochloride,
Sigma) as a cross-linker, as previously described [29] but
with modifications. VP was activated by mixing 6 μl of
DMF, 2 μl of 10 mg/ml VP and 2 μl of a 25-mg/ml solu-
tion of EDC in DMF. The 10-μl reaction mixture was
incubated at RT for 30 min, followed by the addition of 80
μl of 1 mg/ml mfVII protein in PBS and incubation at RT
for 1 hr. For the control, 80 μl of PBS was added to a sepa-
rate 10 μl-reaction tube. The mfVII-VP conjugate was
separated from unconjugated VP on a Sephadex G50 spin
column (Roche) following the manufacturer's instruc-
tions. After separation, the mfVII-VP conjugate was
scanned on a spectrophotometer (Beckman) from 200
nm to 800 nm to measure the protein absorbance at 280
nm and the absorbance at 689 nm for the VP concentra-
tion.
Flow cytometry and cell ELISA for the binding activity of 
mfVII, mfVII-VP and mfVII/hIgG1 Fc Icon to human and 
mouse breast cancer cells
TF expression on breast cancer MDA-MB-231 and EMT-
6 cells and the non-cancerous CHO-K1 cell line as a nor-
mal cell line control was determined by flow cytometry,
using mouse Icon (mfVII/hIgG1 Fc) at a concentration of
10 μg/ml followed by a 1:50-diluted anti-human IgG Fc
secondary antibody FITC conjugate (Sigma), sorted on a
FACS Calibur (BD Biosciences) as described [2-4].
The binding activity of the mfVII and the mfVII-VP
conjugate was determined by flow cytometry, similarly as
described [2-4], and by cell-ELISA using MDA-MB-231
cells as described below. Briefly, after non-enzymatic dis-
sociation, the cancer cells were blocked in HBSS/10 mM
CaCl2/1% BSA/0.05% NaN3 (FACS buffer as wash and
binding buffer), incubated with 20 μg/ml (protein con-
centration) of mfVII or mfVII-VP conjugate, washed
once, incubated with 20 μg/ml goat IgG anti-murine fVII
(R & D Systems), washed once, and then incubated with
20 μg/ml secondary anti-goat IgG FITC (Vector Labora-
tories). After a final wash, the cells were resuspended in
HEPES buffer (10 mM HEPES pH7.3, 140 mM NaCl, 10
mM CaCl2) supplemented with 2 μg/ml propidum iodide
(to distinguish live cells from dead cells) and analysed on
a FACS Calibur (BD Biosciences). The control was the
same except for omitting the addition of mfVII proteins.
Cell-ELISA was done as follows. MDA-MB-231 cells
were grown overnight in 96-well plates at a density of
20,000 cells per well. Then the cells were washed once
with pre-warmed TBS-Ca-T (10 mM Tris-HCl pH 7.4,
140 mM NaCl, 10 mM CaCl2, 0.1% Tween 20), fixed with
1% paraformaldehyde (J.T. Baker) for 10 min at room
temperature, washed three times with TBS-Ca-T buffer,
and then blocked with 2% BSA at 37°C for 1 hr. After one
wash, the cells were incubated with 0, 0.01, 0.1, 1 and 10
μg/ml mfVII or mfVII-VP conjugate diluted in TBS-Ca-T
at 37°C for 1 hr. After three washes, 2 μg/ml goat anti-
mfVII (R & D Systems) was added to detect mfVII bound
to the cancer cells. After three times washes, 100 μl of
OPD substrate solution (Sigma) was incubated at 37°C for
30 min for color development and then was stopped by
adding 50 μl 4.5 N H2SO4, and A490 nm was read using a
microplate reader (Gemini). Binding activity was pre-
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A490 nm of 0 μg/ml control wells).
Confocal imaging of TF expression on HUVECs with or 
without VEGF stimulation
HUVECs were grown on glass coverslips in growth
medium with ECGS in six-well plates. After washing four
times with PBS, Human Endothelial SFM (Invitrogen)
was added to starve the cells overnight in order to elimi-
nate TF expression due to stimuli in FBS and/or ECGS. A
final concentration of 1.1 nM VEGF (BD Biosciences) in
the SFM was incubated with the starved HUVECs for
four hours to induce TF expression [30,31]. Unstimulated
HUVEC controls were also starved but were not incu-
bated with VEGF. Then, both the stimulated and unstim-
ulated HUVECs were fixed with 4% paraformaldehyde for
20 min at RT, washed three times with HBSS-T (HBSS,
0.1% Triton-X 100, 10 mM CaCl2), blocked with 1% BSA
in HBSS-T at 37°C for one hour, and then incubated with
10 μg/ml monoclonal anti-human TF (American Diag-
nostica) or 10 μg/ml mouse Icon, followed by an incuba-
tion with 1:50 anti-mouse or human IgG FITC (Sigma).
To make sure these cells were of endothelium origin, the
cells were stained with anti-human CD31 PE conjugate
after staining for TF. The coverslips were mounted with
anti-fade medium (Molecular Probes) on glass slides and
observed and photographed under a confocal microscope
(Zeiss L510).
In vitro PDT
Cells were seeded with 10,000 cells per well in 96-well
plates and grown overnight in growth medium. The next
morning, the cells were incubated with VP, either in
unconjugated form or as mfVII-VP conjugate, in HBSS
supplemented with 10 mM CaCl2, 1% BSA for 90 min at
37°C and 5% CO2. The cells were washed once, and 100 μl
of complete growth medium was added to each well. The
cells were irradiated with a 689 nm laser at various ener-
gies (J/cm2, 689 nm laser with adjustable power 0-300
mW/cm2, B&W Tek Inc). Controls included laser light
alone, no treatment and maximal killing control. The cells
in the maximal killing control were the same as the no
treatment control except that the cells were completely
lysed by the addition of a 1/10 volume of 9% Triton X-100
for 45 min prior to the cell viability assay. Duplicate wells
were used in all experiments.
Cell viability by staining with crystal violet and reading 
absorbance at 595 nm (A595 nm) for loss of monolayer 
adherence to determine the effect of PDT in vitro
The choice of the cell viability assay using crystal violet
staining was based on a previous work [32] with modifi-
cation of reading A595 nm. Mickuvience et al. [32] com-
pared several non-clonogenic assays for determining the
effect of PDT on adherent cells in vitro and found that
crystal violet staining for measuring the loss of mono-
layer adherence was the most sensitive assay, as com-
pared to other non-clonogenic assays including [3H]-
thymidine incorporation, LDH-release, MTT, trypan blue
exclusion and CyQUANT.
The viability assay by crystal violet staining was usually
carried out at two to three days after PDT, when the cells
in control wells reached 95% confluence. Briefly, the cells
were washed once with PBS, then fixed with 3:1 mixed
methanol: acetic acid at RT for 5 min. The plates were air-
dried, and the cells were stained with 0.05% crystal violet
in 20% ethanol for 20 min at RT. After staining, the extra-
cellular dye and background were removed by thoroughly
rinsing the plates with tap water. The remaining cell-
attached dye was dissolved in a 0.1% acetic acid solution
in 50% ethanol. The dissolved dye solution was trans-
ferred into another 96-well plate, and the A595 recorded
on a microplate reader. Blank acetic acid/ethanol solution
was added to the 96-well plates as a blank control. Since
the A595 nm readings in the maximal killing control wells
were always greater than those in the medium alone con-
trol well due to crystal violet staining of the remained cell
membrane debris, the percent of surviving cells (%) based
on the A595 nm was calculated using the formula: Per-
cent of surviving cells (%) = (experimental-maximal kill-
ing average)/(no treatment control average-maximal
killing average) × 100%.
Killing mechanisms of VP PDT
After the cancer cells in 96-well plates were treated by
tPDT or ntPDT as described above, the plates were cen-
trifuged and half of the culture supernatant in each well
was transferred to another 96-well plate for assaying
cytotoxicity, while the original plate with the cells con-
taining the other half of the culture supernatant was
assayed for cell apoptosis. The Apo-ONE Homogeneous
Caspase-3/7 assay (Promega) was used for measuring
caspase-3/7 activity and presented relative fluorescent
units (relative fluorescent units = experimental fluores-
cent units - average fluorescent units in no treatment
control wells) as evidence of apoptosis, and the CytoTox
96 Non-Radioactive Cytotoxicity Assay (Promega) was
used for measuring lactate dehydrogenase (LDH; a stable
cytosolic enzyme that is released upon cell lysis and can
be used as an indicator of necrosis) in the culture super-
natants as evidence of cytotoxicity in the PDT-treated
cancer cells following the manufacturer's instructions.
The percent of cytotoxicity (%) based on the OD490 nm
was calculated using the following formula: Percent of
cytotoxicity (%) = (PDT treated cells-no treatment control
average)/(maximal killing control average-no treatment
control average) × 100%.
Hu et al. BMC Cancer 2010, 10:235
http://www.biomedcentral.com/1471-2407/10/235
Page 5 of 13Animal models of mouse and human tumour xenografts 
and PDT in vivo
The animal study protocol was reviewed and approved by
the Institutional Animal Care and Use Committee of Yale
University. To generate the subcutaneous xenograft
model, mouse breast cancer EMT6 cells were subcutane-
ously injected into female 4-6-week-old Balb/c mice
(Taconic Farms Inc) with 1 or 2 × 106 cells per mouse as
described in the figure legends. When the tumour size
reached about 100 mm3, mfVII-VP or unconjugated VP
was intravenously injected into mice at a final concentra-
tion of 2 μM VP by an estimate of 1 ml of circulating
blood per mouse at a body weight of 20 grams. Control
mice were i.v. injected with sterile saline. After 90 min,
the tumours were irradiated with 689 nm laser light at
105 J/cm2 while the mice were under anaesthesia with
intraperitoneal injection of Ketamine and Xylazine.
There were five mice in each group in all animal experi-
ments. The PDT treatment was done a total of four or six
times, as indicated in the figure legends. The tumour size
was measured in two dimensions with a calliper, and the
tumour volume was calculated by the formula: (width)2
(length)/2, as described previously [2-4]. The percentage
of tumour growth was calculated by the formula: each
individual tumour/its initial volume on day 0 × 100%.
Statistical analyses
The data on in vitro and in vivo effects were presented as
mean values ± standard deviations using Prism 5 (Graph-
Pad Software) and were analysed for significance between
the treated group and the control group using the
ANOVA (single factor, one-way with Tukey's Multiple
Comparison Test or two-way ANOVA) methods. P values
less than 0.05 were considered to be statistically signifi-
cant. For analyses of statistical significance, duplicate
wells in each group were used for all in vitro PDT experi-
ments in tissue culture plates and five mice per group
were used for the in vivo animal studies, unless specified.
The equations for half-maximal effective concentrations
(EC50) were generated and calculated using Microsoft
Excel and Prism 5 software.
Results
Characterisations of extracted VP, mfVII, and mfVII-VP 
conjugate
After extraction, the spectrum of VP is different from
that of visudyne before extraction, and the peak at 280
nm disappeared in the spectrum of VP (Figure 1A). More
importantly, we observed that free VP dye extracted from
visudyne was held in Sephedex G-50 spin columns,
whereas visudyne passed the spin columns into collection
tubes, indicating that the extraction of VP made the
downstream separation of free dye from the conjugated
dye possible by Sephedex G-50 spin columns.
The molecular weight of mfVII was about 52.8 kDa, as
calculated based on the migration in SDS-PAGE (Figure
1B). After conjugation of mfVII-VP, conjugated VP could
be separated from the unconjugated free dye using Seph-
adex G-50 spin columns. Green solution (VP) was only
present in the collection tubes in the reactions containing
both VP and protein. In contrast, the green dye was held
in the resin of the spin columns in the PBS control reac-
tion, indicating that the VP in the collection tubes was
successfully attached to mfVII. Spectrum scanning analy-
ses (Figure 1C) confirmed that the mfVII-VP conjugate
had absorbance peaks at both 280 nm (protein peak) and
689 nm (Q-band of VP peaks), whereas free dye and
mfVII had a single absorbance peak at 689 nm or 280 nm,
respectively. These results indicate that VP was not only
successfully conjugated to mfVII but also that free VP
was separated from the conjugate. The molar ratio of VP
to mfVII protein was 13.1 ± 2.6 (mean ± SD from 15 sep-
arate conjugation reaction experiments).
The flow cytometry (Figure 1D) and cell ELISA (Figure
1E) results showed that both the VP-conjugated mfVII
and unconjugated mfVII had similar binding activity to
breast cancer MDA-MB-231 cells (P = 0.096 by paired t
test in Figure 1E), indicating that attaching the dye did
not reduce the binding activity of mfVII to the cancer
cells.
TF expression on breast cancer cells and HUVECs
As shown in Figure 2, human breast cancer MDA-MB-
231 and murine breast cancer EMT6 cells express TF, but
CHO-K1 cells do not (Figure 2A). The reason for the
choice of a Hamster cell line (CHO-K1) as a TF-negative
cell control is because there were very few immortalised
normal human cells for potential use as the TF-negative
control, one of which used in this study was human
embryonic kidney 293 cell line provided by Dr. Albert
Deisseroth. In addition, TF expression was only detected
by both mfVII/hIgG1 Fc Icon and anti-TF antibody on
VEGF-stimulated HUVECs but not on unstimulated
HUVECs (Figure 2B), indicating that TF is specifically
expressed on angiogenic VECs, such as those in the
tumour neovasculature of human breast cancer from
patients [1] and human melanoma tumor xenografts
from mice [2].
fVII-targeting improved the selectivity for VP PDT
We first optimised the incubation time and showed that
the strongest killing effect of fVII-tPDT (2 μM VP and 60
J/cm2) on human breast cancer MDA-MB-231 cells
occurred when the incubation time with fVII-VP conju-
gate was 90 min (Figure 3A). Therefore, we decided to use
90 min as the drug (fVII-VP conjugate)-laser light inter-
val.
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tPDT had no effect on non-TF expressing CHO-K1 cells
(Figure 2A), as an example of a normal cell line, whereas
ntPDT had the side effect of killing CHO-K1 cells even at
1 μM VP concentration (P < 0.001 for fVII-tPDT vs.
ntPDT at each VP concentration by two-way ANOVA).
Furthermore, fVII-tPDT (60 J/cm2) even at 5 μM did not
have any side effects on a non-TF expressing 293 cell line
(Figure 3C) (P > 0.05 vs. controls by one-way ANOVA
with Tukey's Multiple Comparison Test), whereas ntPDT
(60 J/cm2) had significant effect on 293 cells even at 0.5
μM (Figure 3C) (P < 0.05 or < 0.001 for 0.5 μM and 5 μM
ntPDT as compared to controls and 0.5 μM fVII-tPDT,
respectively, by one-way ANOVA with Tukey's Multiple
Comparison Test). Note that VP and laser alone did not
have any toxicity to the cancer cells (Figure 3A) and nor-
mal 293 cells (Figure 3C). We conclude that fVII targeting
significantly improves the selectivity of VP PDT.
To determine the effect and selectivity of tPDT for
tumour angiogenic VEC, we used HUVEC as normal
VEC control, which does not express TF until being stim-
ulated with VEGF (Figure 2B), a potent angiogenic
growth factor. We showed that fVII-tPDT at 2 μM VP
and a light dose of 36 J/cm2 killed almost 90% of VEGF-
stimulated HUVEC cells (Figure 3D), which represent
angiogenic tumour VECs in pathological angiogenesis,
but had no effect on unstimulated HUVEC cells (Figure
3D) (P < 0.001 at all three VP concentrations for VEGF-
stimulated vs. unstimulated by two-way ANOVA), which
do not express TF and represent normal VECs (Figure
2B). In contrast, ntPDT even at 1 μM VP and the same
light dose (36 J/cm2) killed both the VEGF-stimulated
and the unstimulated HUVEC cells without any selectiv-
ity (Figure 3E) (P > 0.05 for VEGF-stimulated vs. unstim-
ulated by two-way ANOVA), suggesting that fVII
targeting indeed improved the PDT selectivity between
normal and pathological vascular endothelial cells. Since
2 μM VP in fVII-tPDT did not have any effect on killing
normal cell lines in both cases of CHO-K1 and unstimu-
lated HUVEC cells, the VP concentration of 2 μM was
chosen in the efficacy tests of fVII-tPDT in vitro and in
vivo thereafter. Taken together, these results indicate that
tPDT by fVII to TF could not only distinguish tumour
cells from normal cells but could also distinguish tumour
angiogenic VECs from normal quiescent VECs.
Figure 1 Veterporfin (VP), mfVII protein, and the conjugate. A. Spectra of VP and Visudyne. B. Diagram and molecular weight of mfVII protein de-
termined in SDS-PAGE. fVII, peptide, and His are murine fVII with a mutation of K341A, and S peptide (WT or D14N mutant) and an 8-histidine tag. M 
represents standard protein markers. C. Spectra of VP, mfVII protein, and Sephadex G50 spin column-purified mfVII-VP conjugate and PBS-VP control. 
Arrows indicate the Q-band of VP and arrowheads indicate the protein absorbance peak. D and E. The binding activity of VP-conjugated mfVII and 
unconjugated mfVII to MDA-MB-231 cancer cells determined by flow cytometric analysis (D) and cell ELISA (E). Results in A-D are representative of two 
or more experiments.
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The PDT results with breast cancer cell lines showed that
the effect of tPDT was stronger than those of ntPDT on
killing both human and mouse breast cancer MDA-MB-
231 and EMT6 cells with a VP concentration-dependent
response and that fVII targeting decreased by about three
to four fold the EC50 concentration of VP (Figure 4A-B),
indicating that fVII targeting improved the effect. More-
over, when the VP concentration was 2 μM, the EC50 of
the laser energy in tPDT was about half of that in ntPDT
(Figure 4C), further indicating that fVII targeting could
also reduce laser exposure, which could decrease the risk
of side effects of ntPDT.
As shown in Figure 4D, the effect of fVII-tPDT, pre-
sented as percent of surviving cells, was partially inhib-
ited at a ratio of 1:1 (unconjugated mfVII: VP-conjugated
mfVII) (59.4 ± 0.4%) and almost completely inhibited at
ratios of 10:1 and 50:1 (90.6 ± 5.9% and 94.8 ± 4.7%,
respectively), as compared to no addition of mfVII (cell
survival percent was 37.4 ± 14.8% at the ratio of 0:1) (P >
0.05, < 0.05 and < 0.01 for 0:1 vs. 1:1, 10:1 and 50:1,
respectively, by one-way ANOVA), indicating that the
effect was mediated by mfVII binding to TF.
Killing mechanisms induced by VP PDT
The results in Figure 5 show that both apoptosis and
cytotoxicity were induced in the MDA-MB-231 cancer
cells treated by tPDT and ntPDT, but tPDT induced sig-
nificantly stronger apoptosis (Figure 5A) and cytotoxicity
(Figure 5B) than ntPDT (P < 0.0001 by one-way ANOVA
with Tukey's Multiple Comparison Test), which was con-
sistent with the results of therapeutic effect as deter-
mined by clonogenic assay (Figure 5C) (P < 0.0001). The
Caspase 3/7 activity was the highest at 12 hrs compared
to those at 8 and 16 hrs after PDT, and the LDH activity
in the cytotoxicity assays was higher at 1 hr than that at 4
hrs after PDT.
Figure 2 TF is expressed on tumour cells and VEGF-stimulated HUVECs but not on unstimulated HUVECs. A. TF expression was detected on 
breast cancer cell lines but not on CHO-K1 cells by flow cytometry using mouse Icon (mfVII/hIgG1 Fc) protein. B. Selective expression of TF on VEGF-
stimulated HUVECs but not on unstimulated HUVECs was observed and photographed under confocal microscope. HUVECs were stained for TF ex-
pression by mouse Icon or anti-HTF antibody (FITC, green) and then by anti-human CD31 PE (red) to verify that TF-expressing cells were of vascular 
endothelial origin. Results in A and B are representative of two experiments.
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breast cancer
As shown in Figure 6A, fVII-tPDT at 2 μM of VP was
effective in inhibiting the tumour growth of murine
breast cancer in mice (P < 0.01 vs. control by one-way
ANOVA with Tukey's Multiple Comparison Test) (3-4
mice per group in Figure 6A). In contrast, ntPDT did not
have any effect (P = 0.979 by ANOVA single factor).
Moreover, the results in Figure 6B show that tPDT with
either 2 μM or 4 μM VP had significant therapeutic
effects as compared to controls (P < 0.001 vs. control by
one-way ANOVA with Tukey's Multiple Comparison
Test). However, increasing the VP concentration from 2
μM to 4 μM did not significantly further enhance the effi-
cacy (P = 0.744 by ANOVA single factor) (five mice per
group in Figure 6B), indicating that tPDT with 2 μM VP
in the mfVII-VP conjugate reached the optimal therapeu-
tic potential under the experimental conditions (Figure
6B), probably due to the saturation of the binding of the
target cells by fVII in the fVII-VP conjugate. The mice
were observed for any signs of toxicities during the exper-
iments and examined morphologically at the time of
euthanisation. All of the mice, including the controls and
the PDT-treated mice, in the experiment in Figure 6A
were normal, and no metastases were found in any of the
mice. In the experiment in Figure 6B, all of the control
mice had enlarged spleens and one mouse had liver and
peritoneal metastases. All of the mice treated by fVII-
tPDT had no enlarged spleens, but one mouse in the 4
μM fVII-tPDT group had peritoneal metastases, although
its subcutaneous tumour responded to the fVII-tPDT
treatment, suggesting that fVII-tPDT as a localised ther-
apy had a limited ability to penetrate and therefore had
no effect on metastatic or internal tumours located
beyond the penetration ability of the 689 nm laser light.
No other signs of side effects were observed in these
mice.
In addition, whole mouse body weights were measured
during the period of the experiments, and no differences
and no losses of body weight between the control groups
and the treatment groups were observed, indicating that
the tPDT procedure under the studied conditions was not
toxic to mice.
Discussion
Photodynamic therapy is a treatment involving three key
components: a photosensitiser, light, and tissue oxygen. It
can be used as a stand-alone modality or in combination
with surgery, radiotherapy, chemotherapy, or anti-angio-
genic therapy [33] for cancer. However, ntPDT can cause
severe side effects due to the poor selectivity of photosen-
sitisers [18,19]. To overcome the poor selectivity and
improve the effect, targeting of the photosensitisers with
antibody and ligand has been tested [20-24,34-36], with
Figure 3 fVII targeting improves the selectivity of VP PDT. A. Incubation time of fVII-VP and free VP affected the effect of fVII-tPDT and ntPDT (2 
μM, 689 nm laser at 60 J/cm2) on killing MDA-MB-231 cancer cells. However, VP alone without laser irradiation (VP alone) did not have an effect on 
killing the cancer cells. B. Comparison of fVII-tPDT and ntPDT (689 nm laser at 60 J/cm2) for side effects on non-TF-expressing CHO-K1 cells as a normal 
cell line. C. VP PDT (fVII-tPDT or ntPDT with 0.5 or 5 μM VP at 60 J/cm2) for the non-TF expressing 293 line as a normal cell line control. D and E. fVII-
tPDT and ntPDT (689 nm laser at 36 J/cm2) for HUVEC with or without induction of TF expression by VEGF, as seen in Figure 2B. Results in A-D are 
representative of two experiments.
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Page 9 of 13the hope of specifically targeting the diseased cells and
then internalising the photosensitisers into the target
cells.
In this paper, we target the receptor TF for the develop-
ment of a novel fVII-targeted verteporfin PDT. The rea-
son for targeting TF is based on its over-expression in
many types of cancer cells, including solid cancers [1-
6,12,25,37] and leukaemia [38-40], and very importantly
its selective expression in pathological neovascular
endothelial cells in cancer [1,2,4], choroidal neovascula-
ture [7,8] and endometriosis [9] but not on normal VECs
[1,2,4,7,8]. Garen and Hu have targeted TF using its natu-
Figure 4 fVII targeting enhances the therapeutic effect of VP PDT for human and mouse breast cancer cells. A and B. fVII targeting decreased 
the EC50 (crossing with dotted lines) concentration of VP in fVII-tPDT by three to four fold for human (MDA-MB-231) (A) and mouse (EMT6) (B) breast 
cancer lines, compared to ntPDT (689 nm laser for 60 J/cm2). C. fVII targeting also decreased the EC50 (crossing with dotted line) of the laser energy for 
VP PDT (2 μM VP). D. The effect of fVII-targeted VP PDT (2 μM VP, 689 nm laser for 60 J/cm2) could be inhibited by unconjugated mfVII. Results in A-C 
are representative of two experiments.
Figure 5 fVII-tPDT induces stronger levels of apoptosis and cytotoxicity (necrosis) than ntPDT in human breast cancer MDA-MB-231 cells. 
Both fVII-tPDT and ntPDT were carried out at 2 μM VP and 60 J/cm2. A. Apoptosis assay for Caspase 3/7 activity in the PDT-treated cancer cells. B. Cy-
totoxicity assay for LDH release from PDT-treated cancer cells into the culture medium. C. PDT therapeutic effect assayed by crystal violet staining.
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immunotherapy [2-4], which showed dramatic efficacy
for treatment of several types of cancer [2-5], wMD [7,8]
and endometriosis [9] in animal models. The results in
Figure 2B confirmed that TF expression was only
detected on VEGF-stimulated angiogenic HUVECs but
not on unstimulated quiescent normal HUVECs. The
results in Figure 2B also showed that fVII-containing
mouse Icon could bind to angiogenic HUVECs but not
normal resting HUVECs, providing the basis and ratio-
nale that fVII-tPDT that could selectively kill angiogenic
VECs but have no side effects on unstimulated HUVECs
(Figure 3D), whereas ntPDT could not distinguish angio-
genic VECs from normal VECs for killing (Figure 3E).
The reasons for using fVII instead of making antibodies
to TF are that: (i) the affinity (Kda) of fVII to TF (10-12 M)
[14] is far higher than that of antibodies to TF (10-8 to 10-
9 M)[41,42], and (ii) therapeutic and diagnostic fVII-con-
taining proteins can be made in human sequence by DNA
recombinant technologies for future clinical trials and
usages in murine sequence for tests in preclinical studies.
To develop fVII-tPDT, we first tested and conjugated
dimeric Icon protein (fVII/IgG1 Fc, molecular weight
~210 kDa, unpublished data) with various photosensitis-
ers in our preliminary studies. For better penetration into
tumour tissues, we decided to make a smaller monomeric
fVII protein fused with S-tag [26] and His-tag (molecular
weight = 52,800 daltons, Figure 1B). Both the S-tag and
His-tag can be used for purification and detection. In
addition, since the conjugation of photosensitisers to tar-
geting antibodies or ligands could possibly reduce or even
abolish the binding activity of targeting proteins, Alan
Garen and Zhiwei Hu proposed to use S protein/S pep-
tide [26] as a delivery system for the development of tar-
geted PDT, in which S peptide is synthesised with the
targeting protein molecules, e.g., mfVII in this case, by a
recombinant DNA technique and then commercially
available S protein is conjugated with the photosensitisers
(unpublished data). Since conjugation of VP to mfVII did
not affect the fVII binding activities to cancer cells (Fig-
ure 1D-1E), it was not necessary to use the S protein/S
peptide system as the two components delivery system
for the development of VP tPDT in this paper. Neverthe-
less, this S protein/S peptide system could be useful for
those targeting molecules if their binding activities are
reduced or abolished after direct conjugation with photo-
sensitisers for tPDT.
Visudyne is approved for the treatment of wet macular
degeneration in clinical settings and is being tested as
ntPDT for cancer in preclinical studies [43]. In our pilot
studies, we first conjugated fVII protein with Visudyne
using EDC, which had been used in combination with
NHS (N-hydroxysuccinimide) to conjugate a scFv anti-
body to SnCe6 [29]. We observed that free Visudyne
could not be separated from the conjugated dye by Seph-
adex G50 spin columns. This indicated that the other
components in the liposomal formulation of VP could
interfere with the separation of unconjugated VP from
the conjugated dye. Therefore, it was necessary to extract
the active component of benzoporphyrin derivative
(BPD-MA) from Visudyne, which is referred to here as
VP. When using the extracted VP, free VP was held in the
size exclusion Sephadex G50 spin columns when PBS
buffer alone was added to the EDC-activated VP reaction
(PBS-VP control in Figure 1C). This was the reason for
the lack of a Q-band absorbance peak in the PBS-VP con-
trol after being separated by the spin column (Figure 1C).
A better source of VP for the conjugation reaction, of
course, is a chemically synthesised pure formulation of
VP (BPD-MA), which was not available to us at the time
when we carried out the experiments reported here.
Figure 6 fVII targeting improved the effect of VP PDT for the 
treatment of murine breast cancer EMT6 in female Balb/C mice. 
Mouse breast cancer EMT6 cells were subcutaneously injected into fe-
male 4-6-week-old Balb/c mice (Taconic Farms Inc) with 1 × 106 (A) or 
2 × 106 (B) cells per mouse. When the tumour size reached about 100 
mm3, the mice were treated as follows. A. fVII-VP tPDT and ntPDT with 
2 μM VP and a 689 nm laser for 105 J/cm2 were carried out on days 0, 
3, 8, and 11 (arrows). B. fVII-tPDT with a final concentration of 2 or 4 μM 
VP in mfVII-VP was carried out with a 689 nm laser at 105 J/cm2 on days 
0, 4, 6, 9, 13, and 16 (arrows). Control mice were i.v. injected with PBS 
buffer.
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synthesised in pure formulation has been targeted with
homing peptide for VEGF receptor or single chain Fv
antibodies for treatment of wMD [28] and cancer [34,36],
respectively. Although those previous papers used a dif-
ferent conjugation procedure, the molar ratio of VP to
scFv was 14.1:1 [34,36], which is similar to the ratios of
VP to mfVII (13.1 ± 2.6:1, mean ± SD from 15 separate
conjugation reactions). However, Bhatti et al. noticed that
there was 30% of non-covalent binding VP present in the
final conjugates [36], possibly due to inefficient separa-
tion of free dye by the use of a dialysis procedure. Consid-
ering that the molecular weight of mfVII protein (52.8
kDa) is bigger than that of scFv (30 kDa) [36], our results
of VP-to-fVII ratios were not surprising. Bhatti et al. also
found that the IC50 of VP (1.4 μM) in anti-HER2 C6.5
scFv-targeted VP PDT was about four-fold less than that
(5.4 μM) in free VP PDT for the HER 2+ SKOV-3 ovarian
cancer line, indicating that scFv targeting improved the
effect of VP PDT for that cancer line in vitro by about
four fold. Their observations were similar to our results,
although the EC50 of VP in fVII-tPDT (0.25 μM for
human breast cancer MDA-MB-231 and 0.33 μM for
murine breast cancer EMT6 in Figure 4A-4B) was about
one fifth or one third of that (1.4 μM) in the previous
paper [36]. In vivo studies were not done with scFv-VP or
free VP PDT in the previous papers [34,36]. In this paper
we showed that fVII-tPDT had a significantly stronger
effect than ntPDT for the treatment of breast cancer in
mice (Figure 6A). The reason that ntPDT did not have the
effect in vivo but had the effect in vitro is probably
because liposomal components had been removed, so
that the transportation of liposome-free VP to the
tumour mass by intravenous injection was not as efficient
as that of the liposomal formulation of Visudyne,
although there was no problem for transportation
because VP was directly incubated with the test cells.
Further increasing the VP concentration in the fVII-VP
conjugate did not further increase the effect of fVII-tPDT
in the current setting, probably because fVII even at the
lower concentration had reached the saturation binding
to the tumour vasculature. Therefore, it is possible to get
stronger effect by increasing the laser light fluence (but
not VP concentration) in future experiments. Taking the
in vitro and in vivo results reported in this paper together
with the major findings in our recent paper on fVII-tPDT
for wMD [24], we conclude that this novel fVII-targeted
VP PDT improves the selectivity and efficacy of free VP
PDT for the treatment of breast cancer and wMD and
induces apoptosis and necrosis as the underlining mecha-
nisms of action.
For future clinical trials, we have constructed human
fVII proteins with a lys341Ala mutation, similarly by
recombinant DNA technology, for fVII-tPDT for patients
with cancer or wMD. To establish additional proof of
principle, our laboratory has developed and tested
another fVII-tPDT using another potent photosensitiser,
Sn(IV) chlorin e6, and the results showed that fVII-tar-
geted SnCe6 PDT was more selective and also safe for the
treatment of breast and lung cancer in vitro and in vivo in
mice (Hu et al. Breast Cancer Research and Treatment. In
press).
Conclusions
In this paper we describe for the first time the develop-
ment of a novel and effective ligand-targeted PDT for
breast cancer by conjugating fVII, a natural ligand with
high affinity and specificity for TF, with the US FDA-
approved photosensitiser veterporfin. Since TF is specifi-
cally expressed on angiogenic tumour VECs [1-5] and is
also overexpressed by many types of cancer cells includ-
ing solid cancers [1-6,12,25,37] and leukaemia [38-40],
and since fVII-targeted VP PDT showed a stronger effect
and better selectivity than free VP PDT for breast cancer
in vitro and in vivo, we anticipate that this fVII-VP tPDT
could have broad therapeutic potential for primary and
metastatic tumours, not only for breast cancers but also
for other tumours, as long as these tumours are laser
light-accessible and express TF on their tumour cells and/
or tumour VECs.
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